Becton Dickinson and

Q3 FY2026 EarningsFY26 Q3 beat consensus across all key financial metrics, with revenue of $4.98B vs. $4.89B expected and adjusted EPS of $3.23 exceeding the $3.14 consensus. Strength was driven by the Interventional segment (+6.4% YoY) and BioPharma Systems (+6.6% YoY), alongside a 33.3% YoY increase in operating cash flow. Management narrowed FY26 adjusted EPS guidance to $12.62-$12.72 (raising the midpoint), signaling continued confidence in the 'New BD' structure post-spinoff.